锡尔图因调节器:从2020年到2024年对专利的审查
Emanuele Fabbrizi1,2, Francesco Fiorentino2,3, Antonello Mai1
1Department of Drug Chemistry and Technologies, Sapienza University of Rome, Rome, Italy.
Expert opinion on therapeutic patents
|November 4, 2025
概括
本综述涵盖了关于Sirtuin调节器的近期专利 (2020-2024年),这些调节器对衰老,新陈代谢和癌症等疾病至关重要. 这些Sirtuin激活剂和抑制剂提供了新的治疗途径.
科学领域:
- 生物化学和分子生物学
- 药理学和药物发现
- 遗传学和表观遗传学
背景情况:
- 赛尔图因是DNA修复,基因组稳定性和细胞信号传递的关键调节者.
- 赛尔图因失调与包括癌症,衰老和神经退行性疾病在内的病理有关.
- 针对性调节Sirtuin异型是一种治疗研究的关键领域.
研究的目的:
- 审查2020年至2024年间发布的关于sirtuin调节器的专利.
- 提供在这一时期开发的最相关的Sirtuin调节器的概述.
- 突出Sirtuin激活剂和抑制剂的治疗潜力.
主要方法:
- 使用PubMed,谷歌专利和Espacenet进行了系统的专利搜索.
- 审查的重点是2020年至2024年发布的专利.
- 识别和分析了有关Sirtuin调节器的相关专利.
主要成果:
- 该审查涵盖了Sirtuin调节器专利最近的进展.
- 讨论了具有治疗潜力的关键Sirtuin激活剂和抑制剂.
- 突出的是新兴的技术,如用于异构体特定降解的 PROTACs.
结论:
- 赛尔图因调节剂对于应对衰老,代谢障碍,癌症和神经退行至关重要.
- 激活剂在与年龄相关的疾病中表现有前途,而抑制剂在瘤学中有效.
- 药物设计和查方面的持续进展有望为复杂疾病提供革命性的治疗方法.
相关概念视频
Covalently Linked Protein Regulators
8.6K
Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
These groups modify specific amino acids in a protein....
8.6K
FDA Approved Drugs: Changes to Approved Drugs
214
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
214
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
PI3K/mTOR/AKT Signaling Pathway
5.2K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.2K

